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Lysine.specific cleavage of P2-microglobulin in amyloid deposits asso-
ciated with hemodialysis. Amyloid fibnls isolated from bone and carpal
synovia of seven patients on long-term hemodialysis were further
characterized biochemically. In addition, renal amyloid stones of three
dialyzed patients were examined. All deposits and stones were of
beta2-microglobulin-origin (AB-amyloid) by immunohistochemical and
immunochemical evaluation. Amyloid fibril extracts were dissolved in
80% formic acid and separated by high performance liquid chromatog-
raphy in 60% formic acid and 20% 2.propanol. Three major retarded
fractions with molecular weights of approximately 24, 12 and 7 to 10 kD
were recovered. N-terminal amino acid sequence analysis documented
beta2-microglobulin (/32m) as the principal polypeptide in all investi-
gated cases. In addition to proteins with intact N-termini, one fragment
commencing with isoleucine in position 7 was found in osseous or
synovial amyloid. In renal amyloid stones, one additional fragment was
found beginning with serine in position 20. Generally, these data point
to proteolytic cleavage carboxyterminal to a lysine residue and estab-
lish that not only intact flm but also at least one /32m fragment is
present in /32m.derived amyloid deposits of patients with long-term
hemodialysis. The fragmentation pattern is consistent with the action of
lysine-specific protease(s) and underscores a potentially important role
of limited proteolysis in the pathogenesis of AB-amyloid deposits.
In patients on long-term hemodialysis, the appearance of
/32-microglobulin (f32m)-derived amyloid deposits' has recently
been recognized [1]. The prevalence of amyloid deposits in-
creases continuously with the duration of dialysis. Deposits are
mainly located in joint capsules, synovial membranes, carpal
tunnel structures, subchondral bone and bone marrow [2], thus,
differing strongly from other amyloid syndromes with respect to
'Abbreviations are:
/32m - beta2-microglobulin
AA - amyloid A fibril protein
AA - amyloid fibril protein of immunoglobulin A-light chain origin
AK - amyloid fibril protein of K-chain origin
AF - amyloid fibril protein of prealbumin/transthyretin origin
AC - amyloid fibril protein of cystatin C origin
AB - amyloid fibril protein of /32m origin
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preferential anatomical locations. Results of size determina-
tions or amino acid sequence analysis of intact N-termini
and—in one case [3] of complete amino acid sequence—led to
the conclusion that only intact /32m molecules are deposited
[3—5]. This view was apparently further supported by the report
that intact /32m was transformed into amyloid fibrils in vitro
under extreme conditions of ionic strength and 32m concentra-
tion [61. In contrast, this laboratory documented and reported
the presence of /32m fragments in synovial amyloid deposits [7]
and renal amyloid stones [8]. Fragmentation of f32m may be
important with respect to the mechanism of amyloid fibril
formation. Consequently, we decided to carry out a systematic
analysis to determine whether truncated 132m molecules are
consistently found in j32m-derived amyloid. We also tried to
elucidate the pattern of f32m fragmentation by further analyzing
the N-terminal amino acid sequence of AB-amyloid fibril pro-
teins of several hemodialysis patients. The amyloid was ob-
tained from diverse anatomical sites. Our data establish that
/32m fragmentation is common in AB-amyloid and suggest that
lysine-specific limited proteolysis plays a role in amyloidogen-
esis.
Methods
The main clinical features of the investigated patients and the
source of the specimens are listed in Table 1. A gelatinous
brown mass was obtained at surgery after pathologic fracture
from an amyloidoma of the head of the left femor (patient WIE).
Synovial membrane and femoral bone marrow of a femur were
obtained from patient KRO at autopsy. Patient KRO had been
treated by CAPD and had experienced several acute episodes of
peritonitis. Using cuprammonium membranes, 200 ml of ultra-
filtrate were obtained during dialysis of patients FIC and BEC.
All specimens were immediately frozen at —70°C, shipped on
dry ice and then stored at —80°C. Routine paraffin sections were
available for immunohistochemical classification of the amyloid
deposits.
Diagnosis and immunohistochemical classification
Amyloid deposits were identified by the alkaline Congo red
method [9]. Chemical specificity was diagnosed immunohisto-
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Table 1. Clinical and diagnostic procedures from patients with AB-amyloidosis and/or hemodialysis
identification of
.Patients
Age Clinical syndrome with renal
AB-amyloid
in joint
tissue and/
Treatment
duration
polypeptdes; antigenic/
chemical analysis
1D/
Name (yr) Sex failure or bone (yr) Specimens IP ME [Refi
TAB 60 m amphotericin toxicity NT HD (II) renal calculus (a +) inc. /32m (8)HEZ 55 m chronic glomerulonephritis
WOE 59 m chronic glomerulonephritis
NT
yes
no HD
HD (IS)
renal calculus
carpal synoviab
(u +)
(a +)
NT /32m (8)32m m (7)
HE! 53 w chronic glomerulonephritis NT HD (I) renal calculus (n +) inc. /32m Table 2HEX 59 m chronic glomerulonephritis NT HD (4) renal calculus (n +) NT 132m Table 2
WIE 53 w polycystic kidney disease yes HD (8) bone amyloidomab (o +) f32m /32m Table 2KRO 70 w familial polycystic kidney disease
MAR 68 m familial polycystic kidney disease
yes
yes
HD (13)
HD (20)
bone marrowb
caput femoris"
(a +)
(o +) /32m fl2m
Table 2
j32m 132m Table 2C
HOF no other clinical data available
PAL 74 m chronic glomerulonephritis
yes
yes
HD (?)
HD (8)
caput femoris
caput femonsb
(0 +)
(a +) f3m j32m
Table 2C
/32m fm Table 2CKUR 37 w chronic pyelonephritis yes HD (18) carpal synovia (o +) /32m j32m Table 2C
FIC 63 w polycystic kidney disease no HD (3) ultrafiltrate (d —) NA 13m Table 2
BES 44 m chronic glomerulonephritis yes HD (10) ultrafiltrate (d —) NA /32m Table 2
Abbreviations are: yr. years; w/m, women/man; NT, not tested; HD, hemodialysis; lP, immunoperoxidase technique on tissue sections; inc.,
inconclusive results; NA, not applicable; ID/ME, immunodiffusion/microextraction followed by ID.
Abbreviations are: a, obtained at autopsy; u, excreted in urine; o, surgical specimen; d, during dialysis; n, origin unknown; +, amyloid in
specimen; —, no amyloid in specimen.
b With radiolucencies
Preparation in proteinase inhibitors
chemically on formalin-fixed paraffin sections from patients
HEI, HEX, WIE, KRO, FtC, BES, MAR, HOF, PAL and
KUR. The indirect and the unlabeled immunoperoxidase tech-
niques, as well as the specificities of the antibodies, have been
described in detail elsewhere [7, 10—12]. When immunohisto-
chemical results were equivocal, the microextraction method
was applied followed by immunochemical analysis [13].
Isolation of amyloidfibril proteins
Extraction of amyloid fibril proteins from autopsy or biopsy
specimens, dot blot analysis, immunodiffusion, and isolation
procedures were essentially carried out as described elsewhere
[7, 8]. Lyophilized amyloid fibril concentrates, which were
obtained using the classical water extraction method, contained
more than 80% amyloid according to examination of material
dried on glass slides (stained with alkaline Congo-red [9] and
examined in polarized light). Dry proteins were dissolved in
80% formic acid/H20, centrifuged at 15,000 rpm for 30 minutes
(RC-5B centrifuge, DuPont Instruments, Wilmington, Dela-
ware, USA), and separated according to size on an Ultropac
TSK G2000SW (7.5 x 300 mm) column (LKB-Pharmacia,
Freiburg, FRO) in 60% formic acid and 20% 2-propanol using
HPLC equipment (LKB-Pharmacia) [7, 81. Polyacrylamide
gradient slab-gel electrophoresis, which allows resolution of
low molecular weight proteins, was done according to Hashi-
moto et al [14].
The isolation of AB-proteins of patients MAR, HOF, PAL
and KUR was carried out in a proteinase inhibitor cocktail
containing 0.1 mM leupeptin (Serva, Heidelberg, FRO), 1 mi
benzamidine (Sigma, Deisenhofen, FRG) and 6 mrt EDTA (E.
Merck, Darmstadt, FRG).
Amino acid sequence analysis
N-terminal amino acid sequence analysis was carried out on
a model 470 A gas phase sequenator (Applied Biosystems,
Foster City, California, USA) as described by Mewick et al
[15]. Released PTH amino acids were detected "on line" by a
PTH amino acid analyzer (Model 120A).
Determination of enzyme activity
Soluble proteins extracted from amyloid-containing tissue of
patient MAR preserved without proteinase inhibitors, and those
of patients MAR, HOF, PAL and KUR containing the protein-
ase inhibitor cocktail (see above), were investigated for protein-
ase activity including thrombin, plasmin, kallikrein and trypsin
activity as described elsewhere [16—18]. In addition, purified
f32m was examined using the same assay systems.
Diagnosis and antigenic classification of amy/old deposits
Before extraction, all specimens were examined for the
presence of amyloid deposits [9]. In addition, amyloid deposits
were examined either by immunohistochemical techniques
alone (patients WIE, KRO) or using in addition (HEI, HEX)
microextraction [131. Amyloid of all patients was of /32m origin.
Other amyloid syndromes presenting different amyloid fibril
proteins, such as, AA, AA, A,, AF, AC were excluded in all
patients (Table 1), except in patient KRO whose heart sections
contained small deposits of vascular amyloid that stained with
anti-AA and anti-132m antibodies. Since the bone marrow amy-
bid of KRO reacted only with anti-132m, bone marrow was used
for amyloid extraction.
Purification of AB-amyloid fibril proteins
The elution profile on HPLC of amyloid fibril proteins from
four different patients is presented in Figure 1. All eight cases
(A to D, representative cases) showed a constant major peak
(fraction c) that eluted with a molecular weight of approxi-
mately 12 kD and a minor peak (fraction b) of approximately 24
kD. In addition, peaks of variable size exceeding 30 kD (frac-
tion a) were noted. Fraction d contained polypeptides cone-
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Fig. 1. HPLC-e!ution pattern of different AB-proteins. All amyloid
preparations (except B) were concentrated, lyophilized, dissolved in
80% formic acid and 20% 2-propanol, and separated by HPCL as
described in Methods. For clinical features, see Table I. A. Renal
calculus of patient HEI (extracted twice in phosphate buffered saline by
homogenization and sedimentation (15,000 rpm, for 30 mm). Sediment
was dissolved in 80% formic acid before separation by HPLC. Approx-
imately 0.5 mg material was applied in 100 sl. B. Amyloid concentrate
from a renal calculus (patient HEX) containing considerable salt
incrustations was separated in 6 M guanidine-HCI on Sephadex G-l00,
dialyzed and lyophilized. The major retarded peak of approximately 10
kD was subsequently separated by HPLC. Approximately 0.75 mg was
applied in 75 l. C. Bone marrow amyloid concentrate from patient
KRO. Approximately 2.5 mg were applied in 250 p1. D. Amyloid
concentrate from an amyloidoma of patient WIE. Approximately I mg
was applied in 100 p1.
sponding to molecular weights of 12 kD or below. Recovery
was usually above 80% as reported previously [7, 8]. Since the
renal amyloid stone of patient HEX contained a considerable
amount of salt incrustations, the soluble proteins were first
separated on Sephadex G-100 in 6 M guanidine-HCI (not
shown), dialyzed against H20, and lyophilized. The major
retarded peak of approximately 10 kD was then separated by
HPLC (Fig. lB).
It should be noted that in Figure 1 the peaks of the amyloid
fibril proteins separated from renal amyloid stones have a broad
base indicating size heterogeneity [81. In addition, most poly-
peptides of renal amyloid stones appear to be smaller than 12
kD. This size was also confirmed by SDS-polyacrylamide gel
electrophoresis.
Dot blot analysis and immunodiffusion analysis demonstrated
that all peaks reacted with anti-p2m; precipitation of the higher
molecular weight fractions, however, was weaker than ex-
pected on the basis of binding tests [7]. Fraction C, e and f were
not subjected to further analysis.
To further define molecular weights of the fractions obtained
Fig. 2. SDS-gradienl slab-gel elect rophoresis of amyloid KRO. HPLC-
separated amyloid fibril proteins of patient KRO. Letters (a—d) corre-
spond to respective fractions in Figure IC: U = ultrafiltrate; B =
partially purified f32m, p2m-dimer is also visible; M = molecular weight
standard markers, from top to bottom (molecular weights in KD):
ovalbumin (44); myoglobin (equine heart) (17, 3); /32m (12); recombinant
eglmn-C (8, 1); protein AA (predominant band of 6); insulin B-chain
(3, 5). Arrows indicate protein band of f32m.
by HPLC, SDS-slab gradient polyacrylamide gel electrophore-
sis was employed. A representative slab gel in Figure 2 presents
the size determination of the amyloid fibril proteins for patient
KRO. Lane a represents molecules larger than 30 kD which
entered the gel only partially, lane b the dimer, and lane c the
monomer of 132m. Lane d depicts j32m fragments, in addition to
apparently intact /32m.
When ultrafiltrates obtained from patients on dialysis were
dialyzed against H20 (Spectra/Por 6, MWCO 1000, diameter
28.6 mm; Biomatic Co., Sinsheim, FRG), the lyophilized pow-
der dissolved in 80% formic acid and separated like the AB-
amyloids (Fig. 1). The elution profiles showed a major fraction
of approximately 12 kD (not shown). On immunodiffusion, this
material precipitated with anti-f32m which resulted in a line of
complete identity with f32m (not shown). In contrast to AB-
amyloid, ultrafiltrates did not show proteins smaller than 2m
on SDS-gradient slab gel electrophoresis (Fig. 2, lane U).
N-terminal amino acid sequence analysis
The results of the N-terminal amino acid sequence analysis of
AB-amyloid fibril proteins obtained from different patients on
long-term hemodialysis are presented in Table 2. The following
points are emphasized:
(1) In all of our cases examined, the N-terminal sequences
established that 132m was the parent molecule of the amyloid
under study. This finding confirms reports by Gejyo et al [2, 3]
and others [7].
5 10 5 10
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Table 2. N-terminal amino acid sequences of AB-amyloid proteins from different patients and controls
Pat. Peptide %t 1 5 10 15 20 25 30 35 Ref
/32m IQR TPKIQVYSRHPAENGKSNFLNCYVSGFHPSDI.. . [36]
TAP AB7 IQVYSRHPA,.. SNFLNoYVSGFHP... [8]
WOE AB12 70
30
IQR TPKIQVYSRHPAENGKSNFLN0YVSG...IQVYSRHPAENGKSNF... [7]
AB24 70
30
IQR TPKIQVYS..IQVYSRHPA...
HE1 AB7.12A,c 30
50
20
IQR TPKLQVYSRHPA...IQVYSRHPAENGKSN...SNFLNoYVSGFHPoD...
HEX AB10B,c 50
40
10
IQR TPKLQVYSRHPAENGK...
IQVYSRHPAENGKSNFLN...SNFLNoYVSGFHPoDI.. .
WIE AB>35C,a IQRdTP...
AB24C,b
AB24C,d
90
10
70
30
IQR TPKIQVYSRHPAENGKS...IQV...
IQR TPKIQVYSRHPAENGKS...
IQVYSRHPAENGKSNF...
KRO AB12D,c 90
10
IQR TPKIQVYSRHPA...
LQVYSRHPAENGK,,.
AB7.12D,d 60
20
20
IQR TPKIQVYSRHPA,..JQVYSRHPAENGKSN...SRHPooNG...
MAR AB712 75
25
IQR TPKIQVYSRHPAENGKS...
IQVYSRHPAENGK0NFL...
HOF AB712 60
40
IQR TPKIQVYSRHPAENGKSNFLN...
IQVYSRHPAENGKSNFLNoYV...
PAL AB712 60
40
IQR TPKIQVYSRHPAENGKSNFLN...
IQVYSRHPAENGKSNFLN0YV,..
KUR AB712 60
40
IQR TPKIQVYSRHPAENGKSNFLN...
IQVYSRHPAENGKSNFLN0YV0GFH...
FIC /32m12 IQR TPKIQVYSRHPA...
BES /32m12 IQR TPKIQVYSRHPA...
Major fragments, subscript denotes molecular weight in kD; A,c; B,c etc. denotes fractions of Fig. I
b Fraction in percent, estimated from amino acid recovery
C Larger fragments (9 and 12 kd) were not investigated [8]
o not recovered
d not recovered with certainty
Bold face letters represent N-terminal amino acid. AB-proteins of patients MAR, HOF, PAL and KUR were isolated in the presence of an
enzyme inhibitor cocktail (see Methods).
(2) The fragmentation pattern of amyloid fibril proteins from
different patients and different anatomical sites were similar.
(3) The N-terminus of all amyloid fibril proteins was hetero-
geneous. Three different polypeptides were the main constitu-
ents of amyloid: (i) those with the unfragmented N-terminus of
132m; (ii) fragments commencing with isoleucine in position 7;
and (iii) fragments commencing with serine in position 20. An
additional cleavage site subsequent to tyrosine in position 10
was demonstrated only in patient KRO.
(4) The two f32m fragments starting with position 7 and 19 are
consistently found in renal amyloid stones, whereas only the
fragment starting with isoleucine in position 7 is detected in
amyloid of bone, synovialis and carpal tunnel. This finding
suggests differences in the 132m fragmentation process between
renal and extrarenal sites.
(5) No amino acid substitution compared to /32m was detected
to date in any of the polypeptide sequences examined so far [5,
36].
(6) With one exception (mentioned under c), cleavage oc-
curred exclusively in a position carboxyterminal to a lysine
residue, that is, with lysine in position 6 and 19. Cleavage did
not occur carboxyterminal to arginine in position 3 and 12.
(7) The percentage of the different polypeptides calculated
from the yields of PTH amino acids in certain degradation
cycles, that is, cycle 4, varied in the different fractions obtained
by HPLC. Whereas more than half of the polypeptides in the
fibrils of amyloid kidney stones were cleaved at the N-terminus,
only approximately 20% of the polypeptides in bone marrow
amyloid were cleaved at the N-terminus.
(8) The N-terminal fragmentation found in the 24 kD fraction
indicates polymerization of J32m fragments in AB-amyloid for-
mation (or degradation of a f32m dimer).
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(9) One fraction with molecular weight above 35 kD (Fig. 1C,
a, void volume) also had an intact N-terminus. The high
background and decreasing yield made it difficult to evaluate
the various minor protein specimens.
(10) The high molecular weight fractions containing material
reacting with f2m antibodies were only partly reducible with
disulfide reagents. The major proportion was not reducible,
indicating polymer formation independent of interchain disul-
fide bridging [7].
(11) When /32m was separated from plasma ultrafiltrates in 80
to 60% formic acid, only intact N-termini were found and the
molecular weight, as assessed by SDS-slab gel electrophoresis,
was that of intact 132m. Ultrafiltrate was obtained from one
patient with and one without clinical evidence of detectable
AB-amyloid fibrils. This finding excludes the possibility that
/32m fragmentation observed in AB-amyloid fibrils is a proce-
dure-related artifact.
This conclusion was further substantiated by demonstrating
absence of proteinase activity from tissue extracts, using assays
specific for thrombin, plasmin kallikrein, and trypsin from
tissue extracts.
Although no proteinase activity was demonstrable, sufficient
amounts of proteinase inhibitors were present as a safeguard
during all steps of isolation. In addition, we showed that
purified f32m was devoid of proteinase activity.
Discussion
Our results establish that amyloid associated with long-term
hemodialysis is composed of different polypeptides, all of which
originate from f32m. This observation contradicts previous
studies [3—5] in which only intact f32m was identified in AB-
amyloid fibrils. Apart from intact /32m, we identified truncated
f32m molecules from which three different peptide sequences
were missing at the N-terminus: a hexapeptide, an enneade-
kapeptide and a dekapeptide sequence. The first peptide (/32m
1-6) was missing in amyloid fibrils from bone marrow, bone
amyloidoma, synovial membrane and material from carpal
tunnel; the first and second peptide (J32m 1-19) were missing in
two renal amyloid stones, and the third (f32m 1-10) in bone
marrow amyloid fibrils. These results show that AB-amyloid
deposits of different organs are not identical. This conclusion is
further supported by the finding that AB-amyloid fibrils in renal
stones apparently contained more reducible polymers than
bone or synovial amyloid deposits.
It is interesting to note that the third polypeptide (commenc-
ing with serine in position 11) was identified in an amyloid fibril
preparation from an especially large amount of starting mate-
rial. It is, therefore, conceivable, that additional minor 2m-
derived fragments may be discovered when more starting
material is available in future studies.
To resolve the different molecular weight species of AB-
amyloid by chromatography, we have empirically found that a
high percentage of formic acid is superior to guanidine-HCI for
separation of HPLC [8]. This methodical improvement allowed
us to recover all proteins that had been seen on SDS-polyacryl-
amide gel electrophoresis from the AB-amyloid fibrils. It is
possible that, by using a high percentage of formic acid, we
avoided selective enrichment of the most soluble moiety from
AB-amyloid, that is, intact f32m.
Cleavage at the N-terminus of 132m in AB-amyloid fibrils was
not a random event. As documented in the eight cases investi-
gated in this study and in two other cases published elsewhere
[7, 8], fragmentation did generally occur by cleavage of a bound
carboxyterminal to a lysine. Even though limited proteolysis is
a hallmark of amyloid formation [19—22], lysine-specific cleav-
age of amyloid-forming proteins has not yet been reported. We
conclude that one (or more) proteolytic enzyme(s) are involved
in the generation of AB-amyloid fibrils. Obviously, such en-
zymes must differ from those which are operative in the
formation of other types of amyloid deposits.
We carefully excluded an artifact of the isolation procedure
as a cause of fragmentation: first, no proteinase activity could
be detected in the material isolated and, second sufficient
proteinase inhibitors were present during all steps of the isola-
tion procedure.
Proteolytic activity can be effective only when free enzymatic
activity is present as a result of a (local) excess of proteinase
over the ubiquitous proteinase inhibitors. The site where such
local imbalance occurs could be an intracellular compartment.
Two candidates are conceivable. Phagocytes have been identi-
fied in the vicinity of AB-amyloid deposits in synovial mem-
brane [7] and cells containing amyloid fibrils [23]. Whether
phagocytes remove amyloid fibrils or generate proteolytically
modified peptides from precursor 132m molecules remains to be
clarified. /32m fragments may either provide the "nucleus" for
fibril formation locally by assembly into amyloid fibrils or else
merely be incorporated into pre-existing fibrils of intact /32m.
Another site of f3m fragmentation could be the hemodialysis
membrane. Adhesion of cells and degranulation with release of
proteinases occurs during hemodialysis [24—26]. Bjerrum et al
[27] demonstrated that during degranulation, large amounts of
f32m are released from neutrophils. Concurrent release of pro-
teolytic enzymes with partial exclusion of plasmatic proteinase
inhibitors during frustrated phagocytosis may provide a micro-
environment favoring fragmentation of 132m.
Plasmin [281 and trypsin-like enzyme(s) [29] are candidates
for lysine-specific cleavage of 132m. Plasmin is activated on
dialysis membranes [25]. It splits fibrin subsequent to lysine and
to some extent also subsequent to arginine [28]. Alternatively,
trypsine-like enzyme may be released from lysosomes during
frustated phagocytosis and cause lysine specific cleavage.
Size determination of AB-amyloid fibril proteins revealed
/32m fragments with molecular weights as low as 7 kD. Since the
size deficit is not fully accounted for by the peptides missing at
the N-terminus, it must be assumed that cleavage also occurs at
the C-terminus [8]. It is unknown whether lysine-specific frag-
mentation can also occur at the C-terminus. It remains unre-
solved whether molecules with an intact N-terminus can be
truncated at all at the C-terminus. Several additional potential
cleavage sites within the 32m molecule are present, such as
lysine 75, 91 and 94. Association by coprecipitation of intact
and fragmented amyloid precursor proteins within amyloid
deposits has been recognized for all major amyloid classes [19].
Analogous to other amyloidogenic precursor peptides, it is
likely that generation of J32m fragments alters conformation and
exposes hydrophobic peptide stretches on the surface, thereby
lowering activation energy of fibril formation. This hypothesis
is consistent with our finding of loss of lysine residues with the
attendant loss of cationic e-amino charges.
Our finding of truncation at the N- and possibly C-terminus
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permits the assumption that certain N-terminal and possibly
C-terminal peptide sequences of the fm molecule are not
required for AB-amyloid formation, The data suggest the pres-
ence of "amyloid generating peptides" [30] commencing at
position 7 or 20 of the /32m molecule. Such "amyloid generating
peptides" were identified in amyloidogenic molecules homolo-
gous to /32m, that is, in two Bence Jones proteins from patients
with AL-amyloidosis [301.
Proteolytically modified f32m have been noted in various
systemic diseases thus documenting that limited proteolysis
may occur in vivo. Nissen, Thim and Christensen [31] showed
that /32m of one patient with lung cancer was cleaved after
serine in position 57 and antecedent to aspartic acid in position
59. This resulted in removal of lysine in position 58, thus
altering molecular charge and opening the disulfide loop of the
f32m molecule.
Moreover, a heptapeptide of f32m has been identified in
plasma of patients on long-term hemodialysis with the carboxy-
terminal, lysine in position 19, which is in line with our results
on renal amyloid stones in three patients [32].
Finally, truncated /32m derived peptides with lower p1 have
recently been demonstrated in the blood of dialysis patients
[33], further corroborating our hypothesis.
In summary, we have demonstrated that not only intact 132m,
but also f32m fragments can be detected in AB-amyloid fibrils.
Cleavage was not random but occurred subsequent to lysine
residues. Cleavage of f32m may be a prerequisite for AB-
amyloid formation, since elevated 32m levels found in hemodi-
alyzed patients [34] do not correlate with the presence of
AB-amyloidosis [35]. We propose that specific enzymatic mod-
ification of the /32m molecule leads to removal of hydrophilic
peptide sequences and thus increases hydrophobicity of the
remnant molecule so that ensuing conformational changes favor
amyloid formation. The site where proteolysis occurs, that is,
circulation, cell surface or intracellular space, and the en-
zyme(s) involved, have not been identified. Further identifica-
tion will help not only to understand the unique preferential
localization of AB-amyloid in osteoarticular structures, but also
to develop therapeutic strategies to interfere with the process of
amyloid formation.
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Note added in proof
Recently we have isolated one acidic fragment of 2m from the
ultrafiltrate of a patient on long-term hemodialysis (12 years HD, with
AB-amyloid synovial fluid sediment) and found an intact N-terminus.
This finding indicates an alteration of the iJm molecule distant from the
N-terminus in this case.
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